Skip to Content

Abiraterone

In the US, Abiraterone (abiraterone systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Prostate Cancer.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L02BX03

CAS registry number (Chemical Abstracts Service)

0154229-19-3

Chemical Formula

C24-H31-N-O

Molecular Weight

350

Therapeutic Categories

Antineoplastic agent

Antiandrogen

Chemical Name

17-(3-Pyridyl)androsta-5,16-dien-3β-ol (WHO, BAN)

Foreign Names

  • Abirateronum (Latin)
  • Abirateron (German)
  • Abiratérone (French)
  • Abiraterona (Spanish)

Generic Names

Brand Names

  • Aberic
    Ingerics, Argentina
  • Abiranova
    Celnova, Argentina
  • Abirapro
    Glenmark, India
  • Abiraterona
    Perulab, Peru
  • Adyard
    Microsules Arg, Argentina
  • Birat
    Everex-Oriental, Argentina
  • Kestava
    Bioprofarma, Argentina
  • Prosterona
    Lab. Int. Arg., Argentina
  • Rexinth
    Richmond, Argentina
  • Roterona
    Varifarma, Argentina
  • Tebiran
    Aspen, Argentina
  • Zytiga
    Janssen Pharmaceutica, Serbia; Janssen-Cilag, Bosnia & Herzegowina; Janssen-Cilag, Brazil; Janssen-Cilag, Lithuania; Janssen-Cilag, Latvia; Janssen-Cilag, Poland; Janssen-Cilag, Tunisia; Janssen-Cilag International, Cyprus; Johnson & Johnson, Turkey
  • Abiraterone
    Drugs Technology, Russian Federation; IIHR, Russian Federation; Pharmstandard, Russian Federation
  • Abiraterone-Humanity
    BDR Pharmaceuticals, Georgia
  • Abitera
    Pharmasyntez, Russian Federation
  • Bitera
    Tuteur, Argentina
  • Kigar
    Dosa, Argentina
  • Zytiga
    Janssen, Canada; Janssen, Chile; Janssen, Denmark; Janssen, Finland; Janssen, Hong Kong; Janssen, Ireland; Janssen, Malaysia; Janssen, Norway; Janssen, New Zealand; Janssen, Philippines; Janssen, Sweden; Janssen, Singapore; Janssen, Slovakia; Janssen, Thailand; Janssen Biotech, United States; Janssen Cilag, Argentina; Janssen Pharmaceutical, Japan; Janssen-Cilag, Australia; Janssen-Cilag, Belgium; Janssen-Cilag, Colombia; Janssen-Cilag, Czech Republic; Janssen-Cilag, Estonia; Janssen-Cilag, Spain; Janssen-Cilag, France; Janssen-Cilag, United Kingdom; Janssen-Cilag, Macedonia; Janssen-Cilag, Netherlands; Janssen-Cilag, Peru; Janssen-Cilag, Portugal; Janssen-Cilag, Vietnam; Janssen-Cilag International, Iceland; Janssen-Cilag International, Romania; Janssen-Cilag International NV, Greece; Janssen-Cilag International NV, Slovenia; J-C Healthcare, Israel; Johnson & Johnson, Croatia (Hrvatska); Johnson & Johnson, Indonesia; Patheon Inc, Oman
  • Zytiga 250mg
    Janssen, Luxembourg; Janssen-Cilag, Switzerland; Janssen-Cilag, Germany; Janssen-Cilag International, Austria
  • Zytiga 500mg
    Janssen-Cilag, Switzerland; Janssen-Cilag, Germany; Janssen-Cilag International, Austria
  • Zyvalix
    LKM, Argentina

Glossary

TermDefinition
BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide